ASD
Defiance Autism Impact ETF
The Defiance Autism Impact ETF aims to invest in companies that are actively engaged in addressing the needs of individuals with autism and related developmental disorders, promoting innovative solutions and supporting the autism community.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 1.4 M
ASSETS UNDER MGMT
79 bp
EXPENSES
Fund Basics
| Inception date | Jun 01, 2026 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| PERKINELMER INC | 3.3 % |
| ELI LILLY & CO | 3.3 % |
| DAINIPPON SUMITOMO PHARMA CO | 3.1 % |
| NOVARTIS AG | 3.0 % |
| H LUNDBECK A/S | 3.0 % |
| TAKEDA PHARMACEUTICAL CO LTD | 3.0 % |
| MEDICOVER AB - B SHARE | 3.0 % |
| TEVA PHARMACEUTICAL IND LTD | 3.0 % |
| ROCHE HOLDING AG | 3.0 % |
| ABBVIE INC | 3.0 % |
Constituent Breakdown
| Number of holdings | 33 |
| Herfindahl-Hirschman Index | 264 |
| Wgt avg mkt cap (mns) | $92,878 |
| Large cap (>$10bn) | 47.5% |
| Mid cap ($2-10bn) | 30.6% |
| Small cap (<$2bn) | 7.2% |
| Developed mkts. | 80.5% |
| Emerging mkts. | 5.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 52.2 % |
 |
JAPAN | 11.4 % |
 |
BRITAIN | 5.5 % |
 |
SWITZERLAND | 3.1 % |
 |
ISRAEL | 3.0 % |
 |
SOUTH AFRICA | 2.7 % |
 |
FRANCE | 2.6 % |
 |
MALAYSIA | 2.6 % |
 |
IRELAND | 2.3 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -- | -- | -- | -- | -- | -- | -- | 9.3% |
| Dividend Yield | -- | -- | -- | -- | -- | -- | -- | 0.0% |
| Total Returns | -- | -- | -- | -- | -- | -- | -- | 9.3% | Ann. Volatility | -- | -- | -- | -- | -- | -- | -- | 15.7% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.00 | 0% |
| MSCI EAFE | 0.00 | 0% |
| MSCI Emg Mkts | 0.00 | 0% |
Liquidity Measures
| Avg. volume (000) | 2 |
| ADV traded (mns) | $0 |
| Turnover | 4.0% |
| Avg. Bid/Ask (% of price) | 0.39% |
Technical Indicators
| 30d moving avg. (EMA) | $27.10 |
| Relative strength (RSI) | 52 |
| MACD/Signal | 0.11/0.06 |
| Bollinger Bands (Upper/Lower) | $27.77/$26.21 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. ASD |
Expenses vs. ASD |
ALTAR Score™ vs. ASD |
|---|---|---|---|---|
| PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | 22.6% | -66 bp | +3.3% |
| IXJ | iShares Global Healthcare ETF | 18.1% | -41 bp | +3.2% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 18.0% | -19 bp | +3.2% |
| JDOC | JPMorgan Healthcare Leaders ETF | 18.0% | -14 bp | +2.3% |
| PJP | Invesco Pharmaceuticals ETF | 16.6% | -21 bp | +4.7% |
| PPH | VanEck Pharmaceutical ETF | 15.8% | -43 bp | +4.5% |
| HRTS | Tema Heart & Health ETF | 15.3% | +20 bp | -0.7% |
| IHE | iShares U.S. Pharmaceuticals ETF | 15.1% | -42 bp | +2.9% |
| MEDX | Horizon Kinetics Medical ETF | 14.7% | +6 bp | -1.3% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 14.4% | -44 bp | -3.5% |
Risk and Returns: ASD vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/6/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
2.5%
ALTAR SCORE™
20nd
PERCENTILE
UNDERWEIGHT
ETFRC RATING
There are 746 funds in the Global Equity category with an average
ALTAR Score™ of 4.8% and a standard deviation
of 2.6%. ASD's ALTAR Score™ is approximately -0.9 standard
deviations above the category average. This places ASD in the 20nd percentile
among funds in the category.
Sell-Side Consensus
$32.27
PRICE TARGET
+18.1%
UPSIDE